Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mogamulizumab - Kyowa Hakko Kirin

Drug Profile

Mogamulizumab - Kyowa Hakko Kirin

Alternative Names: AMG-761; KW-0761; Mogamulizumab-kpkc; Poteligeo

Latest Information Update: 07 Feb 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kyowa Hakko
  • Developer Amgen; Bristol-Myers Squibb; Kagoshima University Dental School; Kyowa Hakko; Kyowa Hakko Kirin; Ono Pharmaceutical
  • Class Antiasthmatics; Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CCR4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cutaneous T-cell lymphoma; Peripheral T-cell lymphoma; Adult T-cell leukaemia-lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Adult T-cell leukaemia-lymphoma; Cutaneous T-cell lymphoma; Peripheral T-cell lymphoma
  • Registered Mycosis fungoides; Sezary syndrome
  • Phase III Spinal cord disorders
  • Phase I/II Solid tumours
  • No development reported Non-small cell lung cancer
  • Discontinued Asthma; Hypersensitivity

Most Recent Events

  • 26 Nov 2018 Registered for Mycosis fungoides (Second-line therapy or greater) in European Union, Iceland, Norway, and Liechtenstein (IV)
  • 26 Nov 2018 Registered for Sezary syndrome (Second-line therapy or greater) in European Union, Iceland, Norway, and Liechtenstein (IV)
  • 30 Sep 2018 Discontinued - Phase-I for Solid tumours in Japan (IV) (Kyowa pipeline, November 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top